STOCK TITAN

Theriva Biologics (TOVX) Stock News, Oct 12-24, 2022

TOVX NYSE

Theriva Biologics, Inc. develops therapeutics for cancer and related diseases as a diversified clinical-stage biotechnology company. Its subsidiary, Theriva Biologics, S.L., is developing an oncolytic adenovirus platform for intravenous, intravitreal and antitumoral delivery. The company’s lead candidate, VCN-01, is designed to replicate selectively within tumor cells and degrade the tumor stroma barrier associated with cancer treatment resistance.

Recurring Theriva Biologics news includes VCN-01 clinical data in metastatic pancreatic ductal adenocarcinoma and retinoblastoma, regulatory interactions with U.S. and European agencies, medical-conference presentations, and operational financial results. Coverage also includes SYN-004, or ribaxamase, for gastrointestinal degradation of certain IV beta-lactam antibiotics, and the licensed SYN-020 recombinant intestinal alkaline phosphatase program.

Rhea-AI Summary

Theriva Biologics (TOVX) announced an oral presentation highlighting the encouraging biological activity of VCN-01 in combination with durvalumab at the 14th International Oncolytic Virotherapy Conference in Japan. The Phase 1 study focuses on patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). The presentation, scheduled for October 25, 2022, will be delivered by COO Frank Tufaro. This research may support further development of VCN-01 as a viable treatment option in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.57%
Tags
-
Rhea-AI Summary

Theriva Biologics, formerly known as Synthetic Biologics, Inc. (NYSE American: TOVX), announced a rebranding to reflect its focus on developing innovative oncolytic viruses for cancer treatment. The new branding will be visible with the stock trading under the ticker symbol TOVX starting October 13, 2022. The company highlighted its lead clinical program, VCN-01, aimed at improving tumor treatment, alongside the preclinical program VCN-11. Theriva aims to significantly impact patients with high unmet needs through its advanced therapies, reinforcing its commitment to addressing challenging cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none

FAQ

What is the current stock price of Theriva Biologics (TOVX)?

Theriva Biologics (TOVX) last closed at $0.1440.

What is the market cap of Theriva Biologics (TOVX)?

The market cap of Theriva Biologics (TOVX) is approximately $6.6M.